An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignancies.

Trial Profile

An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Patupilone (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 10 Nov 2009 Actual patient number (5) added as reported by ClinicalTrials.gov.
    • 10 Nov 2009 Actual end date (1 Nov 2006) added as reported by ClinicalTrials.gov.
    • 28 Jan 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top